利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.039 秒)

    Hydroxamic and carboxylic acid derivatives
    3.
    发明授权
    Hydroxamic and carboxylic acid derivatives 失效
    羟肟酸和羧酸衍生物

    公开(公告)号：US06465468B1

    公开(公告)日：2002-10-15

    申请号：US09623835

    申请日：2000-03-22

    申请人： Andrew Douglas Baxter ,  David Alan Owen ,  Duncan Batty ,  Robert John Watson

    发明人： Andrew Douglas Baxter ,  David Alan Owen ,  Duncan Batty ,  Robert John Watson

    IPC分类号： C07C31113

    CPC分类号： C07D213/74 ,  C07C311/13 ,  C07C311/21 ,  C07D211/96 ,  C07D215/58 ,  C07D295/26 ,  C07D307/81

    摘要： The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF &agr; or a condition involving a membrane-shedding event that is mediated by a metalloproteinase. Compounds of the invention are of formula I (B)2N—X—(CH2)m—W—(CR1R2)n—COY  (I) wherein n=0 or 1; m=0 or 1; X is S(O)1-2; Y is OH or NHOH; W is aryl or heteroaryl; and the other groups are as defined herein.

    摘要翻译： 本发明涉及在治疗与基质金属蛋白酶，ADAM或ADAM-TS酶相关的病症中有效的方法和化合物，其由TNFα介导的病症或涉及由...释放的膜脱落事件的病症 金属蛋白酶。 本发明的化合物具有式Iwhereinn = 0或1; m = 0或1; X是S（O）1-2; Y是OH或NHOH; W是芳基或杂芳基;其它基团如本文所定义。

    Hydroxamic and carboxylic acid derivatives
    10.
    发明授权
    Hydroxamic and carboxylic acid derivatives 失效

    公开(公告)号：US06680338B2

    公开(公告)日：2004-01-20

    申请号：US09777522

    申请日：2001-02-06

    申请人： John Gary Montana ,  Andrew Douglas Baxter ,  David Alan Owen ,  Robert John Watson

    发明人： John Gary Montana ,  Andrew Douglas Baxter ,  David Alan Owen ,  Robert John Watson

    IPC分类号： A61K31351

    CPC分类号： C07D401/12 ,  C07C309/08 ,  C07D309/08

    摘要： Compounds having therapeutic utility are of formula (I) B—X—(CH2)n—CR2R3—CR4R5—COY  (I) wherein n=0-1; X is S(O)0-2; Y is OR1 or NHOH; R2 and R4 are independently H or a group (optionally substituted with R10) selected from C1-6 alkyl, C2-6 alkenyl, aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkyl-heteroaryl, heterocycloalkyl, C1-6 alkyl-heterocycloalkyl, cycloalkyl and C1-6 alkyl-cycloalkyl; and R1, R3 and R5 are independently H or C1-6 alkyl, provided that not more than two of R2, R3, R4 and R5 are H; or any of CR2R3, CR4R5 and CR2—CR4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R10 or a group (optionally substituted with R10) selected from C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl and C1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R6 or R7) bonded through carbon to X, or C1-6 alkyl-heterocycloalkyl (optionally substituted with R6 or R7), or a group (substituted with R6) selected from C1-8 alkyl, C2-6 alkenyl and C2-6 alkynyl; R6 is N(R7)2, OR7, COR7, C(═NOR9)R7, NR7R8, S(O)0-2R9 or SO2N(R7)2; R7 is H or a group selected from C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkyl-heteroaryl, cycloalkyl, C1-6 alkyl-cycloalkyl, heterocycloalkyl and C1-6 alkyl-heterocycloalkyl, wherein said group is optionally substituted with R9, COR9, SO0-2R9, CO2R9, OR9, CONR1R9, NR1R9, halogen, CN, SO2NR1R9 or NO2, and for each case of N(R7)2 the R7 groups are the same or different or N(R7)2 is heterocycloalkyl optionally substituted with R9, COR9, SO0-2R9, CO2R9, OR9, CONR1R9, NR1R9, NR1R9 halogen, CN, SO2NR1R9 or NO2, R8 is COR7, CON(R7)2, CO2R9 or SO2R9; R9 is C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl or C1-6 alkyl-heteroaryl; and R10 is OR7, COR7, CO2R1, CON(R7)2, NR7R8, S(O)0-2R9, SO2N(R7)2, CN, halogen or cycloimidyl (optionally substituted with R1); and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and protected hydroxamic acid derivatives thereof.